CD70 is an appealing immunotherapeutic target due to its low expression in non-neoplastic cells, including a limited subset of normal lymphocytes and dendritic cells [75], and high expression in many hematologic cancers and some solid tumors [73,74,75]. The gene discussed is CD70; the disease is hematopoietic and lymphoid cell neoplasm.